<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568968</url>
  </required_header>
  <id_info>
    <org_study_id>2017/2083</org_study_id>
    <nct_id>NCT03568968</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease</brief_title>
  <acronym>NOPARK</acronym>
  <official_title>A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NOPARK is a double-blinded randomized controlled trial that studies nicotinamide
      supplementation in early Parkinson's disease.

      Parkinson's disease (PD) is a major cause of death and disability and has a worldwide
      socioeconomic impact. It affects ~2% of the population above the age of 65 years and its
      prevalence increases dramatically as the population ages. The etiology and molecular
      pathogenesis underlying PD remain unknown. Recent evidence has implicated an impaired
      neuronal metabolism due to mitochondrial dysfunction, in particular NAD-deficiency is a
      key-event in the pathogenesis of PD. We propose that in order to correct this metabolic
      defect and treat PD, we need to boost neuronal NAD levels. This would improve mitochondrial
      function and could slow PD progression. Nicotinamide riboside is a precursor NAD vitamin. In
      this study we will investigate if nicotinamide riboside supplementation will correct NAD
      deficiency and thereby slow progression of PD symptoms. This study will recruit 200 patients
      with newly diagnosed PD and randomly assign them in an 1:1 ratio to either nicotinamide
      riboside or placebo administration for 52 weeks. During this trial the investigators will
      determine if nicotinamide riboside delays PD disease progression measured by clinical
      monitoring tools (MDS-UPDRS). Patients receiving nicotinamide riboside supplementation will
      receive a daily dose of 1000mg for the duration of the trial. This trial will also collect
      biological material from participants to see if nicotinamide riboside supplementation
      rectifies NAD deficiency and metabolism deficiencies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with PD (n = 200) will be recruited starting 01/09/2019. Newly diagnosed and/or
      treatment naïve patients will be given Selegiline 10 mg/day PO and Sinemet 100 x 3. Treatment
      efficacy will be assessed upon reexamination every 1 month. If adequate symptomatic relief is
      not achieved, the dopaminergic therapy may be increased by 150 mg levodopa until optimal
      effect or a maximum dose of Sinemet 200 x 3. If adequate symptomatic relief is not achieved
      on this dose, the patient will excluded and further followed-up at the regular outpatient
      service. Once optimal effect is reached (i.e. stable treatment for at least 3 months, the
      regime will be frozen for the duration of the study period (52 weeks). Patients will then be
      randomized to receive either Nicotamide riboside or placebo. Both the participants and the
      investigators are masked. The trial will have a 52 weeks (1 year) exposure period, during
      which patients will self-administer NR 500 mg x 2/day, or placebo per os. In addition, all
      patients will take a stable regime of selegiline 10 mg/day plus optimal dopaminergic therapy.
      After the baseline visit, participants will be reassessed at 4, 13, 26, 39 and 52 weeks in
      person. Clinical evaluation will be performed by one of the neurologists involved in the
      study and/or the study nurse. The primary outcome of the study is the total score of the
      Movement disorder society Unified parkinson's disease rating scale (MDS-UPDRS) comparing the
      NR and and placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized double-blinded study. 400 Participants randomized in 1:1 ratio to either vitamine supplementation or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Both patients and all investigators are blinded during the trial and during data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease rating Scale)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Clinical rating scale approved by mobement disorder society. The Movement Disorder Society Unified Parkinson's Disease rating Scale (MDS-UPDRS) measures multiple clinical disabilities on a scale of 1-4. The subscores are summed providing a total score for MDS-UPDRS. The total score ranges from 0 to 260. Higher score indicates worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NAD metabolism</measure>
    <time_frame>52 weeks</time_frame>
    <description>Levels of metabolites in the NAD metabolites measured from biological material (blood).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets, no active ingredients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside</intervention_name>
    <description>1000mg one time daily. Given as tablets. Duration of the trial, 52 weeks.</description>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <other_name>Chromadex NR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo drug, given 1 time daily for the duration of the trial; 52 weeks.</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a clinical diagnosis of idiopathic PD according to the MDS clinical diagnostic
             criteria for Parkinson's disease.

          2. Positive [¹²³I]FP-CIT single photon emission CT (DaTscan) confirming nigrostriatal
             degeneration

          3. Diagnosed within one year from enrolment

          4. Hoehn and Yahr score &lt;= 2 at enrolment

          5. Optimal symptomatic therapy, not requiring adjustments, for at least 3 months

        Exclusion Criteria:

          1. Dementia or other neurological disorder at baseline visit

          2. Metabolic, neoplastic, or other physically or mentally debilitating disorder at
             baseline visit

          3. Prior use of dopaminergic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charalampos Tzoulis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haukeland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charalampos Tzoulis, MD, PhD</last_name>
    <phone>94392305</phone>
    <phone_ext>+47</phone_ext>
    <email>charalampos.tzoulis@helse-bergen.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brage Brakedal, MD</last_name>
    <phone>99777962</phone>
    <phone_ext>+47</phone_ext>
    <email>bragebrakedal@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arendal Hospital</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Herlofsen</last_name>
      <email>Karen.Herlofson@sshf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charalampos Tzoulis, PhD</last_name>
      <email>charalampos.Tzouolis@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Brage Brakedal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestre Viken Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kari Anne Bjørnarå, PhD</last_name>
      <email>kari.anne.bjornara@vestreviken.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Førde sykehus</name>
      <address>
        <city>Førde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aliaksei Labusau</last_name>
      <email>aliaksei.labusau@helse-forde.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haugesund Hospital</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ida Hogenesch</last_name>
      <email>neke.Hogenesch@helse-fonna.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus university hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krisztina Kunszt Johansen, PhD</last_name>
      <email>krisztina.johansen@ahus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathias Toft</last_name>
      <email>Mathias.Toft@uio.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjørg Warø</last_name>
      <email>bjorg.waro@ntnu.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>NAD metabolism</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>Nicotinamide Riboside</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

